A retrospective analysis of surgical procedures for ovarian tumours, performed in the Department of General and Oncological Gynaecology at the Military Medical Academy (Sofia, Bulgaria) specified 81% of the tumour cases as benignant ones, 15.6% as malignant ones, and 3.4% as borderline ovarian tumours (BOT). The histological type of BOT was assessed as serous in 62% and as mucinous in 38%. The incidence of BOT was found to increase with increasing age. Most patients with BOT were parous (60%). Serum levels of CA 125 were within normal values in all patients with BOT.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters.
Cancer Immunol Immunother
January 2025
Division of Oncology, Department of Clinical Sciences Lund, and Lund University Cancer Center, Lund University, Lund, Sweden.
Tertiary lymphoid structures (TLS) in the tumor microenvironment are prognostically beneficial in many solid cancer types. Reports on TLS in high-grade serous tubo-ovarian carcinoma (HGSC) are few, and the prognostic impact is unclear. We investigated mature TLS (mTLS), immature TLS (iTLS) and lymphoid aggregates (LA) in primary adnexal tumors (PTs) and synchronous omental/peritoneal metastases (pMets) of HGSC.
View Article and Find Full Text PDFTissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.
Cancer Immunol Immunother
January 2025
Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD, 20892, USA.
Tissue factor (TF) is a cell surface protein that plays a role in blood clotting but is also commonly expressed in many cancers. Recent research implicated TF in cancer proliferation, metastasis, angiogenesis, and immune escape. Therefore, TF can be considered a viable therapeutic target against cancer.
View Article and Find Full Text PDF[Tumor-associated macrophages promote pre-metastatic niche formation in ovarian cancer].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
December 2024
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210000, China. *Corresponding author, E-mail:
Patients with ovarian cancer (OC) are often diagnosed at an advanced stage and have a poor prognosis because of extensive tumour metastasis. Tumour metastasis usually occurs in stages, which means that before the invasion of tumour cells, a pre-metastatic niche (PMN) has been formed to support the subsequent colonisation and growth of tumour cells. Tumour-associated macrophages (TAMs) are highly heterogeneous in terms of origin, phenotype and function.
View Article and Find Full Text PDFA trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
Cancer
January 2025
Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma, USA.
Background: Yttrium-90 FF-21101 (Y-FF-21101) is a radiopharmaceutical that targets P-cadherin as a therapy against solid tumors. A previously reported, first-in-human study determined that a dose of 25 mCi/m was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response. In this article, the authors report the results of Y-FF-21101 treatment in an ovarian carcinoma expansion cohort and in patients with selected solid tumors who had known high P-cadherin expression.
View Article and Find Full Text PDFLow-grade endometrial endometrioid carcinoma of the p53-abnormal group: case presentation and diagnostic issues.
Pathologica
October 2024
Pathology Unit, Department of Oncology, ASST Sette Laghi, Varese, Italy.
P53-abnormal endometrial carcinomas are high-grade and aggressive tumors which should be treated with chemo-/radiotherapy. In low-grade endometrioid carcinoma (LGEC), abnormal expression of p53 is an exceptional finding and is typically accompanied by patchy p16 positivity and diffuse hormone receptor expression. Herein, we report a case of LGEC exhibiting both p53 and p16 overexpression, highlighting the diagnostic pitfalls related to such phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!